Collegium Pharmaceutical, Inc. COLL
22.53
(0.11)
(0.49%)
as of 25 Sep
- Market cap
- $737.1M
- P/E
- 14.7×
Follow COLL
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
23.66 | 13.95 | 23.15 | 18.91 |
+8 more quarters Free account |
P/S ratio |
1.45 | 1.33 | 1.88 | 1.46 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
16.48 | 18.58 | 11.93 | 14.08 | |
P/B ratio |
3.77 | 3.40 | 4.87 | 4.02 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.62 | 1.79 | 2.40 | 2.12 | |
EV/EBITDA |
5.42 | 3.44 | 4.62 | 4.21 | |
EV/Operating CF |
6.42 | 4.30 | 5.68 | 5.52 | |
EV/FCF |
(53.00) | (37.04) | (46.03) | (20.36) | |
Quick Ratio |
0.74 | 1.54 | 1.40 | 1.19 | |
Current Ratio |
1.03 | 1.71 | 1.57 | 1.36 | |
Net Debt/EBITDA |
13.77 | 4.17 | 3.45 | 4.24 | |
Debt/Assets |
51.11% | 48.60% | 48.85% | 50.28% | |
Debt/Equity |
3.50 | 2.57 | 2.68 | 2.94 | |
Asset Turnover |
0.43 | 0.49 | 0.47 | 0.47 | |
Operating CF/Net income |
(4.74) | 3.94 | 7.25 | 2.49 | |
Capex/Depreciation |
(0.01) | 0.00 | (0.01) | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
53.33% | 44.62% | 32.92% | 32.05% | |
Intangible Assets out of Total Assets |
0.64 | 0.46 | 0.49 | 0.54 | |
Share Based Compensation of Revenue |
7.25% | 5.62% | 4.75% | 4.69% | |
Graham Net Nets |
(1.03) | (0.56) | (0.45) | (0.65) | |
Graham Number |
18.19 | 22.79 | 20.69 | 19.03 | |
Earnings Yield |
4.23% | 7.17% | 4.32% | 5.29% | |
Free Cash Flow Yield |
(3.40%) | (3.62%) | (2.77%) | (7.14%) | |
Revenue per Share |
6.16 | 6.03 | 6.48 | 6.63 | |
Operating CF per Share |
2.20 | 1.78 | 3.88 | 2.48 | |
Capex per Share |
(0.02) | (0.01) | (0.02) | (0.01) | |
Free Cash Flow per Share |
2.18 | 1.77 | 3.86 | 2.48 | |
Cash per Share |
4.60 | 13.76 | 12.82 | 9.68 | |
Shareholders Equity per Share |
9.61 | 9.74 | 9.51 | 8.70 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
9.61 | 9.74 | 9.51 | 8.70 | |
Free Cash Flow |
70.83 | 56.84 | 122.36 | 78.25 | |
Working Capital |
18.15 | 310.70 | 251.38 | 160.94 | |
Capital Expenditures |
(0.50) | (0.27) | (0.69) | (0.19) | |
Net Current Asset Value |
(1,215.87) | (593.86) | (663.75) | (718.65) | |
EV/EBIT |
13.45 | 7.53 | 10.41 | 10.24 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(7.53%) | 7.49% | 8.26% | 15.05% | |
Price to Operating Income |
7.46 | 5.62 | 8.17 | 7.04 | |
| Other line items | |||||
Average Receivables |
249.06 | 228.74 | 219.93 | 231.20 | |
Average Payables |
10.07 | 12.34 | 7.30 | 5.39 | |
Average Inventory |
75.71 | 39.98 | 38.24 | 38.04 | |
Average Assets |
1,864.21 | 1,641.67 | 1,660.21 | 1,621.24 | |
Average Common Equity |
272.06 | 273.43 | 265.26 | 254.54 |
Columns are period end dates